FYN is overexpressed in human prostate cancer - Wikidata - wikimedia - TriplyDB

FYN is overexpressed in human prostate cancer

FYN is overexpressed in human prostate cancer

http://www.wikidata.org/entity/Q28300097

about

Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases Dynamically Coupled Residues within the SH2 Domain of FYN Are Key to Unlocking Its Activity The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer.Reduced surface expression of epithelial E-cadherin evoked by interferon-gamma is Fyn kinase-dependent A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer Differential transformation capacity of Src family kinases during the initiation of prostate cancer.Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells.Future perspectives of prostate cancer therapy.Fyn Activation of mTORC1 Stimulates the IRE1α-JNK Pathway, Leading to Cell Death High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.Fyn Mediates High Glucose-Induced Actin Cytoskeleton Reorganization of Podocytes via Promoting ROCK Activation In Vitro.SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.Non-Genomic Actions of the Androgen Receptor in Prostate Cancer Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.Mechanisms of androgen receptor activation in castration-resistant prostate cancer Emerging novel therapies in the treatment of castrate-resistant prostate cancer.Src signaling pathways in prostate cancer.A novel BLK-induced tumor model.Targeting Fyn in Ras-transformed cells induces F-actin to promote adherens junction-mediated cell-cell adhesion.Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors.MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells.DNA methylation in promoter region as biomarkers in prostate cancer.Post-translational regulation of COX2 activity by FYN in prostate cancer cells.Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase.Cyclooxygenase 2: protein-protein interactions and posttranslational modifications.Fyn knockdown inhibits migration and invasion in cholangiocarcinoma through the activated AMPK/mTOR signaling pathway.FYNagling divergent adhesive functions for Fyn in keratinocytes.Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors.

P2860

Q26866135-CCBC4D14-94D0-49C0-B014-3AE35C2AEDAC Q27728152-FF24BA85-E267-476B-AD83-5A6C2A7E197F Q28076745-4C23C9F7-7D97-4DEA-A463-7646D65B574C Q28235184-7CAF9524-2CE6-46E3-9D89-FC27C66B1202 Q30501331-74DF494F-C9FA-463C-9CCB-A94FA4017225 Q33426973-4CDBA554-B04D-4086-8E12-1C35EF65C291 Q33643375-C518C974-F285-4B6B-82A3-98F9F384708E Q33787365-FA53F6F0-6665-4B80-B165-C36BABB541CD Q34310254-6185BE01-73BC-4295-901F-8E805B4D03B4 Q34322294-380DC324-8935-45F9-BB9A-1391E38713C4 Q34613941-74063336-EA75-42BE-869A-EF7DD32A76DF Q34835580-F914C979-48FD-4025-B108-74457F7B623D Q35832949-6B85CFA8-A47C-4D57-B9EB-08C33D7DA7E7 Q36076453-A1468B9A-45AF-4D86-A0B9-46023EDAA938 Q36139815-89F6E96B-C1A2-42FA-90CA-235059260CA7 Q36152474-50C6D2D0-7C18-4AEF-B1BE-DC22097FC3E3 Q36531604-E69200C5-DC80-4819-BB80-BA3A8597A7C8 Q36688923-AD001546-90A9-45AC-B8A3-242263B9DD0E Q37185828-E9F9E248-F0F6-4AB1-8E8F-0B9625293D2E Q37502039-627A070C-90F9-409A-803A-AEC2D6943407 Q37588620-79E61741-1F48-4081-A96D-4D64BDBEA497 Q37613072-D3B4A6BC-216A-4478-B791-74F9ADC44868 Q37628940-1DF8C0B8-99B6-499D-876B-507F61BAD156 Q37862392-DD6F1F92-D1B4-47D7-88D8-84AAC3683123 Q38187565-55070E4B-2496-453C-BE29-005E78E113DB Q38698300-4C527110-2DD5-4A1B-90F8-CABB64F329C6 Q38979793-2C4458E0-55FC-464A-9BB6-158D1A014E44 Q41935042-D649BEB5-C83B-409A-9A68-396215658EA5 Q42028379-0326D8B8-29AA-470C-9FC0-CBBF2FEBCC64 Q42261678-57720450-E60A-4DBE-A957-6FB582944250 Q42847206-198D265A-330D-418D-81E3-94E5AA4880E3 Q47608480-FF88C5F4-3D33-4A52-B784-D606DC54F580 Q47758719-6FAFDFBA-E384-492E-8F32-9B34B5576ACC Q50053633-949BA98F-14EB-4814-9CB0-FE50129D95D7 Q54341168-8C99A147-CC6B-4E6D-BCF8-DB9EFC6D592E Q54979375-327AEAE7-CE7D-441F-A91E-876CCCA51621

P2860

FYN is overexpressed in human prostate cancer

http://www.wikidata.org/entity/Q28300097

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

FYN is overexpressed in human prostate cancer

@ast

FYN is overexpressed in human prostate cancer

@en

FYN is overexpressed in human prostate cancer

@nl

type

label

FYN is overexpressed in human prostate cancer

@ast

FYN is overexpressed in human prostate cancer

@en

FYN is overexpressed in human prostate cancer

@nl

prefLabel

FYN is overexpressed in human prostate cancer

@ast

FYN is overexpressed in human prostate cancer

@en

FYN is overexpressed in human prostate cancer

@nl

P1433

Q28300097-D70D676A-788D-421A-9331-F57BA4BC4F71

P1476

Q28300097-78E351E0-523C-4DB8-B9D3-D76F9B2FA3DB

P2093

Q28300097-05AA3823-D11C-48E8-9F41-86B5CAD2B6A2

Q28300097-3440C7B2-3070-4FAE-B363-9D5FA6E70AAE

Q28300097-4C7B8A6A-98AC-4146-8114-9128CBC401B4

Q28300097-594319C4-531B-489F-A0E9-8BEBB7E03B00

Q28300097-5D4C6E95-9980-4F5B-925B-6180AF1B1765

Q28300097-5E7B39D7-AF52-42A7-819F-5F58D3E2EF76

Q28300097-7DDEB77D-DA56-4B4C-9634-5FDFCF580A5C

Q28300097-809A8265-D6B1-4258-83D4-B9C48E877EC4

Q28300097-8648D747-5F68-4B79-9D1C-9E8A8C23CFE7

Q28300097-BD642AE0-BC97-4CCC-8D4C-5759C8208701

P2860

Q28300097-0A3A895C-C474-4C48-9209-0B274D61C172

Q28300097-21F37262-E127-4858-8344-26319A6DED4E

Q28300097-2570D2BE-C57C-4525-8434-FC74522476CE

Q28300097-3545D57A-DC18-4F02-A890-8CBE1E68A273

Q28300097-395C2F97-4914-4A84-98A4-DF5B9EA6C6BA

Q28300097-3FF8AFE4-985C-48BC-8889-F71F390FF902

Q28300097-426CAF60-BECB-42FA-91E4-E0EAFB574906

Q28300097-48CF9552-3FF2-4C4C-A3B1-D330990EFFF0

Q28300097-59D80B92-A471-46C6-B863-02D579573154

Q28300097-629DEA36-48A9-49E2-A767-9D15D00BD476

P304

Q28300097-CD923726-F624-4CF8-BD11-412D12796E33

P31

Q28300097-D4B9DA2A-7809-43BD-84F8-7139D3EE34F5

P356

Q28300097-8FD2AD96-D2BC-4615-86A6-9C08524730D5

P407

Q28300097-83F972D7-331A-4DF1-8511-643F03DDBABD

P433

Q28300097-09B4B974-8333-41B2-A2CF-EA21971C4174

P478

Q28300097-21FDEEDA-232E-4EFA-AB81-E01083429AFC

P50

Q28300097-37103B5F-25B4-4613-81B1-EEAACB218F3C

Q28300097-DCC71D95-99B3-419C-AFD9-3ABA8CC9C224

P577

Q28300097-5013B9DB-E546-489F-91E5-630731F6E6E6

P5875

Q28300097-02C046D4-24D6-49CF-AC37-6CA8BAF65DA6

P698

Q28300097-B102DC04-FAD0-484D-AB41-2956C8E62447

P921

Q28300097-5F4A46F6-6511-47AF-A708-7F5B4A9D1434

P932

Q28300097-E48EF426-E02D-464D-93B4-C36759E0A91F

P356

J.1464-410X.2008.08009.X

P1433

BJU International

P1476

FYN is overexpressed in human prostate cancer

@en

P2093

Carrie Rinker-Schaeffer

http://www.w3.org/2001/XMLSchema#string

Edwin M Posadas

http://www.w3.org/2001/XMLSchema#string

Hikmat Al-Ahmadie

http://www.w3.org/2001/XMLSchema#string

Javed Siddiqui

http://www.w3.org/2001/XMLSchema#string

Kristen E Kasza

http://www.w3.org/2001/XMLSchema#string

Kristen Otto

http://www.w3.org/2001/XMLSchema#string

Maria Tretiakov

http://www.w3.org/2001/XMLSchema#string

Ravi Salgia

http://www.w3.org/2001/XMLSchema#string

Victoria L Robinson

http://www.w3.org/2001/XMLSchema#string

Walter M Stadler

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2008

Fyn, a Src family tyrosine kinase

Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles

Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells.

Expression of focal adhesion kinase in normal and pathologic human prostate tissues.

Integrative molecular concept modeling of prostate cancer progression.

Novel compounds with antiproliferative activity against imatinib-resistant cell lines.

Acquisition of transforming properties by FYN, a normal SRC-related human gene.

Activation of the lutropin/choriogonadotropin receptor in MA-10 cells leads to the tyrosine phosphorylation of the focal adhesion kinase by a pathway that involves Src family kinases

Nonreceptor tyrosine kinases in prostate cancer.

P304

171-177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1464-410X.2008.08009.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Ramasamy Jagadeeswaran

Kenneth J. Pienta

P577

2008-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23457366

http://www.w3.org/2001/XMLSchema#string

P698

18990162

http://www.w3.org/2001/XMLSchema#string

P921

P932

2741693

http://www.w3.org/2001/XMLSchema#string